On September 29, 2020, CentralBio Co., Ltd (KOSDAQ:A051980) closed the transaction. The company has amended the terms of the transaction and received gross proceeds of KRW 8,800,000,000 from Ilias Biologics. The company will issue 14,839,797 shares representing 32.05% stake upon conversion.